

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

ANNOUNCEMENT ON ESTIMATED RESULTS FOR THE YEAR 2024

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

I. ESTIMATED RESULTS FOR THE PERIOD

1. Period of the estimated results

1 January 2024 to 31 December 2024.

2. Estimated results

- (i) Based on the preliminary estimate of the financial department of the Company, it is estimated that the net profit attributable to owners of the parent company for the year of 2024 will range from RMB107,824,000 to RMB127,824,000, which is decreased by RMB150,000,000 to RMB170,000,000 (or decreased by 53.99% to 61.19%) as compared to the same period last year.
- (ii) It is estimated that the net profit attributable to owners of the parent company after deducting non-recurring profit or loss will range from RMB79,128,300 to RMB99,128,300, which is decreased by RMB155,000,000 to RMB175,000,000 (or decreased by 60.99% to 68.86%) as compared to the same period last year.

3. The estimated results have not been audited by a certified public accountant. The Company has conducted preliminary discussions with the auditor of the Company on matters related to the estimated results.

II. RESULTS AND FINANCIAL POSITION FOR THE SAME PERIOD LAST YEAR

1. The total profit for the same period last year amounted to RMB305,905,900, the net profit attributable to owners of the parent company amounted to RMB277,824,000, and the net profit attributable to owners of the parent company after deducting non-recurring profit or loss amounted to RMB254,128,300.
2. The earnings per share for the same period last year amounted to RMB0.72.

III. THE MAIN REASONS FOR THE CHANGE IN RESULTS FOR THE CURRENT PERIOD

In 2024, the net profit attributable to shareholders of the Company and the net profit attributable to shareholders of the Company after deducting non-recurring profit or loss decreased compared with the same period last year, mainly due to the impact of the continuous deepening of the centralized procurement policy.

During the reporting period, the Company actively implemented the national centralized volume-based procurement policy and won the bidding for all joint products in the continuous procurement after the expiration of the state-organized centralized volume-based procurement agreement of artificial joints. In the state-organized centralized volume-based procurement of intraocular lens and sports medicine consumables, all the sports medicine products of the Company won the bidding, and the prices of the Company's related products decreased and gross profit margin declined. In order to cope with the changing industry policies and ensure the stable supply of products that won the bidding in centralized procurement, the Company adjusted the price of channel inventory before the implementation of centralized procurement, resulting in a decrease in revenue and net profit.

IV. RISK WARNING

As of the date of this announcement, the Company has not identified any material uncertainties affecting the accuracy of the estimated results.

V. OTHER EXPLANATORY MATTERS

The foregoing estimated data is a preliminary estimation only. Detailed and accurate financial data of the Company to be disclosed in the 2024 annual report of the Company shall prevail.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 24 January 2025

As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Weng Jie and Mr. Wong Tak Shing.

* *For identification purposes only*